Lexaria Bioscience
- Biotech or pharma, therapeutic R&D
Lexaria Bioscience is an oral based, clinical stage, drug delivery enabling technology company. Its patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream increasing bioavailability, improving speed of onset and increasing brain absorption. It also improves safety and tolerability resulting in lower occurrences of adverse events. The Company's research program is currently focused on the GLP-1 marketplace where its DehydraTECH has been shown clinically to offer superior benefits to the SNAC technology that powers the only commercially available oral GLP-1 (semaglutide) drug product today, while also enabling oral delivery of other GLP-1 drugs (e.g., tirzepatide and liraglutide). The Company also has advanced R&D assets in the areas of oral cannabinoid and nicotine delivery as well.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}